Aim: The aim of the study is to evaluate the glycemic outcomes in temporary use of continuous glucose monitoring (CGM) in patients with type 1 diabetes (T1D) on continuous subcutaneous insulin infusion (CSII) or multiple daily injection (MDI).  
Methods: A CGM for 7 days was added on T1D patients with HbA1c>7.5%. All patients did not use any CGM device in the last three months. Patients were analyzed in two groups: 
CSII group, 28 patients on CSII (Minimed Veo/722, Medtronic, USA) used real-time CGM (Minilink with En-lite sensor, Medtronic, USA) for seven days, where patients could see the glucose value and respond adequately and   
MDI group, 32 patients on MDI used retrospective CGM (Ipro2 with En-lite sensor, Medtronic, USA), where patients could not see the glucose value (blinded CGM).  
Patients from both groups used the CGM device for 7 days.  Data was downloaded using specific software (Carelink Pro and Carelink Ipro, Medtronic, Northridge, CA) and specific instructions in basal and bolus insulin, education on food, physical activity and hypoglycemia/hyperglycemia were given to the patients. HbA1c was obtained before and three months after the study. 
Results: Both groups significantly improved glucose control (HbA1c) from 7.8±0.6% to 7.1±0.6% in CSII group and from 8.2±1.1% to 7.4±0.8% in MDI group. There was no significant difference between both groups at the end of the study.  
Conclusions: Temporary use of CGM can improve glucose control in both T1D patients on CSII or MDI. Further investigation on larger groups should be performed to confirm our findings.

12th International Conference on Advanced Technologies & Treatments for Diabetes